Just a moment, the page is loading...
The Supported Studies Programme
In 2022, GSK’s Consumer Healthcare business will become an independent company through a proposed demerger from GSK. As a result, Consumer Healthcare has developed its own Supported Studies portal. Click here to access the portal.

For the latest updates on GSK’s response to COVID-19, please click here.

Immunology and Specialty Medicine



Timelines





[Daprodustat ISS/SCS Committee. Last updated in May 2022.]
• Clinical practices and behaviours related to the management of anemia of CKD
• Healthcare resource utilisation related to anemia of CKD
• Burden and impact of untreated anemia of CKD across different geographies or related to differential healthcare access, including underserved populations
• Novel technologies to improve patient care and/or the patient experience in the management of anemia of CKD
• Effectiveness of Daprodustat in subgroups of special interest
Including patients not reaching Hb target, inflamed patients, diabetic patients, anephritic patients, home dialysis, peritoneal dialysis, transplant
• New indications (other than anemia of CKD), where Daprodustat could benefit patients


[Nucala ISS/SCS Committee. Last updated in March 2022.]
GSK call for research proposals of relevance to disease understanding and impact of mepolizumab in two disease areas
• Chronic rhinosinusitis with nasal polyps (CRSwNP)
• Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Applications are invited in the following areas
• Real world evidence outcomes and predictors of mepolizumab response
• Impact of mepolizumab in prevention of organ damage and disease progression
• Non-eosinophilic biological effects of interleukin 5 (IL-5)
• Comorbid CRSwNP and Severe Eosinophilic Asthma

[Otilimab ISS/SCS Committee. Last updated in Jan 2022.]
GSK is not accepting new supported study submissions related to otilimab COVID at this time. Any accepted submissions, where funding has been confirmed, will be progressed as planned. Please contact your local GSK office if you require further information. We will publish updates at this site shortly. Thank you.

[Belimumab ISS/SCS Committee. Last updated in May 2021.]
GSK is not accepting new supported study submissions related to Belimumab (Benlysta) at this time. Any accepted submissions, where funding has been confirmed, will be progressed as planned. Please contact your local GSK office if you require further information. We will publish updates at this site should things change. Thank you.

[Sotrovimab ISS/SCS Committee. Last updated in September 2021.]
At this time GSK’s supported study program for Sotrovimab is at capacity addressing prioritized evidence gaps and we are not currently accepting new submissions. Any accepted submissions, where funding has been confirmed, will be progressed as planned.
Please contact your local GSK office if you require further information. We are constantly reviewing our position and will publish updates on this site should things change. Thank you.



Although GSK are more likely to support studies aligned to our current areas of interest for supported studies, we are interested in supporting studies that are innovative and contribute to scientific knowledge relating to a product, a medical condition or advancing a technology.



© 2001-2022 GlaxoSmithKline plc. All rights reserved. Registered in England and Wales No. 3888792.
Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.